Biosceptre Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$11.3M
- Investors
-
3
Biosceptre General Information
Description
Developer of targeted cancer immunotherapies designed to treat a broad range of malignancies. The company offers CAR-T cell therapies, antibody-based therapeutics, cancer vaccines, and its proprietary BRiDGECAR™ platform incorporating nfP2X7-targeted technology, enabling patients to receive targeted immuno-oncology treatments for solid and liquid tumors.
Contact Information
Website
www.biosceptre.comCorporate Office
- Babraham Main Hall
- Babraham Research Campus, Babraham
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Babraham Main Hall
- Babraham Research Campus, Babraham
- Cambridge CB22 3AT
- England, United Kingdom
Biosceptre Timeline
Biosceptre Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 27-Jul-2026 | $11.3M | Completed | Generating Revenue | ||
| 10. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series A) | 05-Feb-2024 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A) | 01-Nov-2023 | Cancelled | Generating Revenue | |||
| 7. Later Stage VC (Series 3) | 06-May-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A) | 21-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC | 06-Jun-2017 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Mar-2016 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC | 01-Oct-2015 | $7.3M | $12M | Completed | Pre-Clinical Trials | |
| 2. Angel (individual) | 09-Jul-2014 | $4.7M | $4.7M | Completed | Pre-Clinical Trials |
Biosceptre Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 2,000,000 | $0.001339 | $1.67 | $1.67 | 1x | $1.67 | 4.5% | |
| Ordinary | 30,000 | $0.001339 | $0.7 | $0.7 | 1x | $0.7 | 0.07% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Biosceptre Comparisons
Industry
Financing
Details
Biosceptre Competitors (98)
One of Biosceptre’s 98 competitors is Agios Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Macrogenics | Formerly VC-backed | Rockville, MD | ||||
| Circle Pharma | Venture Capital-Backed | South San Francisco, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland |
Biosceptre Patents
Biosceptre Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4735479-A1 | Molecules and methods for activating car t cells | Pending | 30-Jun-2023 | ||
| WO-2025000037-A1 | Molecules and methods for activating car t cells | Inactive | 30-Jun-2023 | ||
| EP-4676521-A1 | Chimeric antigen receptors for binding to dysfunctional p2x7 receptor | Pending | 08-Mar-2023 | ||
| WO-2024182858-A1 | Chimeric antigen receptors for binding to dysfunctional p2x7 receptor | Inactive | 08-Mar-2023 | ||
| EP-4587465-A1 | Enrichment of engineered immune cells | Pending | 14-Sep-2022 | G01N33/532 |
Biosceptre Signals
Biosceptre Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jungle Capital | Venture Capital | Minority | ||
| McKenny-McFarlane Capital | PE/Buyout | Minority | ||
| Norcliffe Capital | Venture Capital | Minority |
Biosceptre FAQs
-
When was Biosceptre founded?
Biosceptre was founded in 2004.
-
Where is Biosceptre headquartered?
Biosceptre is headquartered in Cambridge, United Kingdom.
-
What is the size of Biosceptre?
Biosceptre has 15 total employees.
-
What industry is Biosceptre in?
Biosceptre’s primary industry is Drug Discovery.
-
Is Biosceptre a private or public company?
Biosceptre is a Private company.
-
What is Biosceptre’s current revenue?
The current revenue for Biosceptre is .
-
How much funding has Biosceptre raised over time?
Biosceptre has raised $53.1M.
-
Who are Biosceptre’s investors?
Jungle Capital, McKenny-McFarlane Capital, and Norcliffe Capital have invested in Biosceptre.
-
Who are Biosceptre’s competitors?
Agios Pharmaceuticals, Macrogenics, Circle Pharma, CytomX Therapeutics, and Light Chain Bioscience are some of the 98 competitors of Biosceptre.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process